You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV ...

Results Patients with hepatitis B (HBV) were more likely to develop HCC at a younger age than patients with hepatitis C (HCV) (HBV-26% under age 40, HCV-0% under age 40; p < 0.001), with greater ...

Single cell current best practices tutorial case study for the paper:Luecken and Theis, "Current best practices in single-cell RNA-seq analysis: a tutorial" ...

HBV-infected HepG2-NTCP cells were pooled before being divided and shipped to the four participating labs. Every lab received a frozen cell pellet of approximately 1×10 7 cells, which on arrival was ...

The ability of A2-derived HBV vaccines to protect against non-A2 HBV genotypes has recently been brought into question following the publication of a study of 3.7 million blood donors in the USA.

In addition to HBsAg, other viral markers such as hepatitis B core-related antigen (HBcrAg) are available, but their potential association with HBV-specific immune responses is not defined yet, which ...

Chronic hepatitis B virus (HBV) infection is associated with poor COVID-19 outcomes, but vaccination against COVID-19 reduces the risk among coinfected patients. These study findings were published in ...

The White House has thrown its weight behind the lab leak theory, an idea that has divided intelligence agencies. By Benjamin Mueller The Trump administration has replaced the government’s main ...

美国食品药品监督管理局（FDA）已授予 PBGENE-HBV 快速通道资格，这是一种针对成人慢性乙型肝炎患者的试验性基因编辑疗法。 PBGENE-HBV 旨在通过消除病毒持续存在的关键来源——HBV cccDNA（共价闭合环状DNA），并灭活肝细胞中整合的 HBV DNA，从而有望治愈慢性乙型 ...